Misoprostol is a synthetic analogue of prostaglandin E1 (PGE1) that has become a cornerstone of modern midwifery and obstetric care, particularly in resource-limited settings across Nigeria. Originally developed to prevent and treat gastric ulcers caused by nonsteroidal anti-inflammatory drugs, clinicians quickly noticed its powerful effects on the human uterus. In maternity units, it is widely utilized due to its thermal stability—unlike oxytocin, it does not strictly require continuous refrigeration—making it exceptionally valuable for rural clinics and community midwifery practice where power supply can be erratic.
When administered, misoprostol targets specific prostanoid receptors in the myometrium, setting off a cascade of physiological changes.
These dual actions make the drug exceptionally potent for both opening a closed cervix and clamping down a bleeding postpartum uterus.
Misoprostol can enter the body through several distinct routes, each offering a different speed of absorption and peak plasma concentration. Midwives must understand these pathways because bioavailability varies significantly depending on the route chosen.
Midwives encounter misoprostol across various stages of maternity care. Its versatility stems from its ability to prompt uterine activity under different clinical circumstances.
For induction of labor, low doses are used when a pregnancy needs to be terminated or expedited due to formal medical conditions like pre-eclampsia or prolonged rupture of membranes. In the management of incomplete abortion and miscarriage, it helps evacuate retained products of conception safely without immediate surgical intervention. Finally, it serves as a frontline agent for the prevention and treatment of postpartum hemorrhage (PPH), saving countless lives globally where injectable oxytocics are unavailable.
Despite its immense utility, misoprostol is a potent drug that can cause severe harm if misused. The most absolute warning in obstetric practice is its use in women with a previous cesarean section or major uterine surgery. The powerful, uncoordinated contractions triggered by misoprostol can easily rupture a scarred myometrium, leading to catastrophic hemorrhage, fetal distress, or maternal death. It must also never be given concurrently with other oxytocic drugs like oxytocin or ergometrine unless specific sequential protocols are carefully followed, as simultaneous administration leads to uterine hyperstimulation.
Administering misoprostol requires vigilant observation because side effects can appear rapidly. Common and usually self-limiting adverse reactions include transient shivering, elevated body temperature, nausea, vomiting, and diarrhea. However, the most critical parameter to monitor is uterine activity. Midwives must regularly assess contraction frequency, duration, and intensity, alongside fetal heart rate patterns when the fetus is alive. If contractions become too close together or the resting tone of the uterus remains high, immediate intervention is necessary to prevent fetal hypoxia and uterine rupture.